{
    "clinical_study": {
        "@rank": "131040", 
        "arm_group": {
            "arm_group_label": "RUXOLOTINIB", 
            "arm_group_type": "Experimental", 
            "description": "Ruxolotinib : patient with donor HSCT  4 months later patients without donor: ruxolotinib alone"
        }, 
        "brief_summary": {
            "textblock": "JAK2 inhibitor RUXOLITINIB before allogeneic hematopoietic stem cell transplantation  (HSCT)\n      in patients with primary or secondary myelofibrosis : a prospective phase II"
        }, 
        "brief_title": "JAK2 Inhibitors RUXOLITINIB in Patients With Myelofibrosis", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Myelofibrosis", 
        "condition_browse": {
            "mesh_term": "Primary Myelofibrosis"
        }, 
        "detailed_description": {
            "textblock": "JAK2 inhibitor RUXOLITINIB before allogeneic hematopoietic stem cell transplantation  (HSCT)\n      in patients with primary or secondary myelofibrosis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age between 18 and 69 years\n\n          -  No comorbidity contraindicating the transplantation :\n\n               -  Severe respiratory failure defined as dyspnea  grade III or more\n\n               -  Severe cardiac failure defined as  EF < or =  30%\n\n               -  Severe renal failure defined as  creatinine clearance < 30 ml/min or dialysis\n\n               -  Dementia or non-ability to give informed consent for the protocol\n\n               -  Major alteration of performance status defined as  ECOG > 2\n\n               -  Severe liver disease defined as a cirrhosis or bilirubin > 2 x ULN, or AST/ALT >\n                  5 x ULN\n\n          -  Primary or secondary myelofibrosis diagnosed according to WHO definition  (Tefferi,\n             et al 2007)\n\n          -  Palpable splenomegaly or splenomegaly measured by any imagery (maximum size> 15 cm by\n             ultrasound scan, Magnetic Resonance Imaging or computer tomography)\n\n          -  Disease if intermediate or high risk according to published criteria and summarized\n             as follows:\n\n        At least one criterion among the following:\n\n          -  Haemoglobin < 100 gr/L (unrelated to medication toxicity)\n\n          -  Leucocytes < 4 G/L (unrelated to medication toxicity) or > 25 G/L\n\n          -  Poor prognosis cytogenetics :  complex karyotype, abnormalities of  chromosomes 5, 7\n             or 17 , +8, 12p-, inv(3), 11q23\n\n        Two criteria among the following criteria :\n\n          -  General symptoms (weight lost > 10% in less than 6 months, night swears, specific\n             fever > 37.5\u00b0C)\n\n          -  Peripheral blastosis > 1% observed at least twice\n\n          -  Thrombocytopenia < 100 G/L (unrelated to treatment toxicity)\n\n        Exclusion Criteria:\n\n          -  Myelofibrosis transformed into acute leukaemia with 20% blasts of more in blood or\n             bone marrow\n\n          -  Previous treatment with JAK2 inhibitor\n\n          -  Thrombopenia < 50 G/L\n\n          -  Comorbidities contraindicating the transplantation\n\n          -  Comorbidity score Sorror > 3\n\n          -  Pregnant or lactating women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "69 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01795677", 
            "org_study_id": "JAK ALLO STUDY"
        }, 
        "intervention": {
            "arm_group_label": "RUXOLOTINIB", 
            "description": "Ruxolotinib doses calculated with platelets count and P450 cytochrome inhibitor HSCT for patients with donor", 
            "intervention_name": "Ruxolotinib", 
            "intervention_type": "Drug", 
            "other_name": "Kakavi"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "JAK2 inhibitor RUXOLITINIB", 
            "Primary or secondary myelofibrosis"
        ], 
        "lastchanged_date": "June 24, 2013", 
        "link": {
            "description": "Goelams internet site", 
            "url": "http://infodoc.inserm.fr/"
        }, 
        "location": {
            "contact": {
                "email": "vrOlland-neyret@chu-grenoble.fr", 
                "last_name": "Valerie ROLLAND NEYRET, Mrs", 
                "phone": "+3476765096"
            }, 
            "facility": {
                "address": {
                    "city": "Paris", 
                    "country": "France", 
                    "zip": "75010"
                }, 
                "name": "ROBIN"
            }, 
            "investigator": {
                "last_name": "Marie ROBIN, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "JAK2 Inhibitors RUXOLITINIB in Patients With High or Intermediate Risk Primary or Secondary Myelofibrosis Eligible for Allogeneic Stem Cell Transplantation: a Prospective Multicentric Phase II Study", 
        "overall_contact": {
            "email": "marie.robin@sls.aphp.fr", 
            "last_name": "Marie ROBIN, MD", 
            "phone": "33142499639"
        }, 
        "overall_contact_backup": {
            "email": "VRolland-neyret@chu-grenoble.fr", 
            "last_name": "Valerie ROLLAND NEYRET, CRA", 
            "phone": "33 476765096"
        }, 
        "overall_official": {
            "affiliation": "FIM/GOELAMS", 
            "last_name": "MARIE ROBIN, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "DFS is defined as the probability to be alive and in remission", 
            "measure": "DFS", 
            "safety_issue": "Yes", 
            "time_frame": "24 months after inclusion"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01795677"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Rate of pre-graft splenectomy\nCo-morbidity score defined by Sorror et al before RUXOLITINIB and after 4-month treatment just before transplantation\nPost-graft haematological recovery: time to neutrophil engraftment, platelet and red blood cells transfusion independency\nAcute GVHD grade II-IV  incidence\nChronic GVHD incidence\nOverall survival, disease-free survival, non-relapse mortality\nJAK2V617E allele burden and status at registration, 3, 7, 16 months after inclusion (centralization)", 
                "measure": "HSCT", 
                "safety_issue": "Yes", 
                "time_frame": "24 months after inclusion"
            }, 
            {
                "description": "Patients with and without donor\nRate of patients with donor who benefit from a transplantation:\nComorbidity score at registration and after 3 months\nPlatelet and red blood cells transfusion independency\nPerformance status evolution (ECOG)\nGeneral symptoms related to myelofibrosis  (questionnaire MF SAF)\nComparison of haematological response in patients with or without donor\nSpleen size evolution\nComparison of quality of life in patients with and without  (questionnaire EORTC)\nComparison of overall survival in patients with and without donor\nIncidence of severe infections\nCytokine measure at registration, 3, and 7 months after inclusion (centralization)\nMPL JAK status (at registration, centralization", 
                "measure": "PATIENTS CARACTERISTICS", 
                "safety_issue": "Yes", 
                "time_frame": "24 months after inclusion"
            }
        ], 
        "source": "Groupe Ouest Est d'Etude des Leuc\u00e9mies et Autres Maladies du Sang GOELAMS", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Groupe Ouest Est d'Etude des Leuc\u00e9mies et Autres Maladies du Sang GOELAMS", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}